Oscient reiterated by JMP at buy

Oscient Pharmaceuticals Inc. was reiterated by JMP Securities analyst Adam Cutler at a buy rating with a price target on the stock of $6 per share following the weekly prescriptions for its antibiotics Factive and Testim compiled in NDC Health data. Oscient shares Monday were unchanged at $2.39 on volume of 1,608,367 shares versus the three-month running average of 819,671 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.